Last reviewed · How we verify

Camtobell — Competitive Intelligence Brief

Camtobell (BELOTECAN) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: belotecan. Area: Oncology.

marketed belotecan DNA topoisomerase 1 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Camtobell (BELOTECAN) — Chong Kun Dang.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Camtobell TARGET BELOTECAN Chong Kun Dang marketed belotecan DNA topoisomerase 1
Enhertu Enhertu Washington D.C. Veterans Affairs Medical Center marketed DNA topoisomerase 1, Receptor tyrosine-protein kinase erbB-2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (belotecan class)

  1. Chong Kun Dang · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Camtobell — Competitive Intelligence Brief. https://druglandscape.com/ci/belotecan. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: